We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FOSL:NASDAQFossil Group, Inc. Analysis

Data as of 2026-06-30 - not real-time

$4.29

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Fossil’s stock is trading at $4.29, just above its 20‑day SMA of $4.18 but still beneath the 50‑day SMA of $4.36, indicating a modest short‑term upside. The RSI sits near 52, suggesting neither overbought nor oversold conditions. A bullish MACD crossover (histogram positive) and rising volume add momentum to the near‑term view. However, the price remains close to the calculated support at $3.94 and faces resistance around $4.68, limiting immediate gains. Volatility is elevated at roughly 56% over the past 30 days, and a beta above 2 signals pronounced sensitivity to market swings.
On the fundamentals side, revenue has slipped 3.7% YoY and the company posted a negative profit margin of –6.2%, reflecting ongoing earnings pressure. The balance sheet is strained, with debt of $334 M dwarfing cash of $81 M and a debt‑to‑equity ratio north of 400, flagging solvency concerns. Yet the DCF‑derived fair value of about $9.5 implies a potential upside of over 60% versus the current price, and analysts’ median target of $7 reinforces a valuation gap. The price‑to‑sales multiple of 0.25 and a price‑to‑book of 2.4 further suggest the stock is trading at a value‑oriented discount. The recent announcement that Fossil will join the Russell 2000 Index as its turnaround gains traction adds a positive market‑perception catalyst. Overall, the blend of technical bullish signals, substantial valuation upside, but high leverage and earnings volatility creates a nuanced risk‑reward profile. Investors should weigh the upside potential against the debt load and market sensitivity before committing capital.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD crossover
  • Increasing volume
  • Support near current price

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF upside >60%
  • Analyst median target $7
  • Russell 2000 inclusion

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Debt reduction progress
  • Turnaround sustainability
  • Volatility and beta risk

Key Metrics & Analysis

Financial Health

Revenue Growth-3.70%
Profit Margin-6.18%
P/E Ratio-18.7
ROE-58.45%
ROA2.61%
Debt/Equity401.78
P/B Ratio2.4
Op. Cash Flow$-19305000
Free Cash Flow$61.0M

Technical Analysis

TrendNeutral
RSI51.9
Support$3.94
Resistance$4.68
MA 20$4.18
MA 50$4.36
MA 200$3.71
MACDBullish
VolumeIncreasing
Fear & Greed Index89.91

Valuation

Fair Value$9.52
Target Price$7.00
Upside/Downside63.17%
GradeUndervalued
TypeValue

Risk Assessment

Beta2.18
Volatility55.96%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.